• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Wallonia and brussels >A STRATEGIC ROLE IN TAKEDA'S THERAPY PORTFOLIO
【24h】

A STRATEGIC ROLE IN TAKEDA'S THERAPY PORTFOLIO

机译：武田疗法的战略作用

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

What shows the strategic role of the Lessines manufacturing site for the whole Takeda Pharmaceutical Company: with more than 1,200 employees, Lessines is the group's third-largest production site, and a centre of excellence for immunoglobulin purification. The buildings on the site cover 18,000 m~2 and the plant operates 24/7. It is flexible, with packaging facilities for plasma-derived therapies and conditioning capacities for hematological products. The Lessines site also hosts an R&D unit focused on improving purification processes. "Takeda Lessines has a legacy of nearly 50 years of continuous and sustained investment by local, state and federal governments. We will continue our efforts and look to the future with optimism, ready to partner with all those who share our ambition: to provide better care for patients, develop our people, and preserve the planet", says Geoffrey Pot, General Manager Operations at Takeda Lessines and Chair of bio.be, the Belgian federation representing companies that are active in the biotech and life sciences industry.
机译：显示了整个武田制药公司的Lessines制造地点的战略作用：Lessines是该集团的第三大生产地点，也是免疫球蛋白纯化的卓越中心。现场的建筑物覆盖18,000 m〜2，该工厂的运营24/7。它是灵活的，具有血浆衍生疗法的包装设施和血液学产品的调理能力。 Lessines网站还托管了一个专注于改善纯化过程的研发单元。 “武田·莱西因斯（Takeda Lessines）拥有近50年的遗产，由地方，州和联邦政府进行了持续和持续的投资。我们将继续努力并以乐观态度向未来展望未来，并准备与所有分享我们野心的人合作：提供更好武田莱斯丁斯（Takeda Lessines）总经理运营，比利时联邦（Belgian Federation）代表活跃于生物技术和生命科学行业的公司的BEIO.BIO。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号